common myths about pbpk modeling and simulation- busted!
Published 4 years ago • 1.6K plays • Length 3:39Download video MP4
Download video MP3
Similar videos
-
50:49
pbpk modeling and simulation for regulatory decision making: impact on us prescribing information
-
59:49
pbpk modeling approaches to assess risks associated with bioequivalence in drug development
-
55:39
a best practice framework for applying pbpk modeling to pediatric drug development
-
1:02:16
leveraging dermal pbpk modeling and simulation approaches
-
1:52
pbpk modeling supports approval of breakthrough cancer drug
-
45:25
exploring new and improved analytical methods for traditional and unique modalities
-
37:50
2 pbpk modeling using pk-sim
-
36:06
simcyp in vitro (data) analysis (siva) toolkit for biopharmaceutics
-
49:40
pbpk modeling and simulation: bridging the “bottom up” and “top-down” approaches
-
59:17
strategic application of pbpk models for predicting ddis & the effects of smoking & organ impairment
-
40:57
precision dosing using pbpk modeling
-
1:03:46
how lc-ms proteomics is revolutionizing pbpk modeling and simulation
-
4:22
fact or fiction: is pbpk a substitute for clinical ddi data?
-
59:17
applications of pbpk modelling for regulatory submissions: case studies
-
13:20
developing compound files for pbpk modeling in the simcyp simulator
-
1:01:14
pbpk modeling & simulation to support asciminib nda submission and inform drug product label
-
59:23
first-in-human (fih) faster: the power of physiologically based pharmacokinetic (pbpk) modeling
-
20:08
1 introduction to pbpk modeling